The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample by Morant, N et al.
1 
 
The Least Worst Option: User experiences of antipsychotic medication and lack of 
involvement in medication decisions in a UK community sample 
 
 
 
 
Authors: 
Nicola Morant 1 
Kiran Azam2 
Sonia Johnson1 
Joanna Moncrieff 1,2* 
 
 
 
 
 
 
1 Division of Psychiatry, University College London, Maple house 149, Tottenham Court 
Road, London W1T 7NF, United Kingdom, Tel 02076799424.  
2 North East London NHS Foundation Trust, Research & Development department, 
Goodmayes Hospital, Barley Lane, Goodmayes, Essex, United Kingdom.   
* corresponding author j.moncrieff@ucl.ac.uk, Tel 03005551201X65714 
 
 
  
 
2 
 
The Least Worst Option: User experiences of antipsychotic medication and lack of 
involvement in medication decisions in a UK community sample 
 
Abstract 
Background: Treatment decision-making that fully involves service users is an aim across 
medicine, including mental health.  
Aims: To explore service users’ experiences of taking antipsychotic medication for psychotic 
disorders, and their perceptions of decision-making about this.  
Method: Semi-structured interviews with 20 users of community mental health services, 
conducted by service user researchers and analysed using thematic analysis.  
Results: Antipsychotic medication was perceived to have beneficial effects on symptoms and 
relapse risk, but adverse effects were prominent, including a global state of lethargy and 
demotivation. Weighing these up, the majority viewed antipsychotics as the least worst 
option. Participants were split between positions of ‘willing acceptance’, ‘resigned 
acceptance’ and ‘non-acceptance’ of taking antipsychotics. Many felt their choices about 
medication were limited, due to the nature of their illness or pressure from other people. They 
commonly experienced their prescribing psychiatrist as not sufficiently acknowledging the 
negative impacts of medication on life quality, and physical health concerns, and described 
feeling powerless to influence decisions about their medication.  
Conclusions: The study highlights the complexity of agendas surrounding antipsychotic 
medication, including the pervasive influence of coercive processes, and the challenges of 
implementing collaborative decision-making for people with serious mental health problems. 
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Introduction  
Antipsychotic medication is the principal form of treatment for people with schizophrenia 
and long-term psychotic conditions. Despite their effectiveness in reducing acute symptoms 
and risk of relapse (Leucht et al., 2008, Leucht et al., 2012), antipsychotics produce an array 
of adverse effects and may contribute to reduced subjective life quality and functioning 
(Bebbington et al., 2009, Hofer et al., 2004, Wunderink et al., 2013, Wykes et al., 2017).  
Research on experiences of medicine-taking highlights how people evaluate medication use 
according to personal goals, values and circumstances, weighing up factors including 
symptom reduction, adverse effects, stigma and inconvenience (Donovan & Blake, 1992, 
Karp, 1993, Pound et al., 2005, Venn & Arber, 2012, Zhou, 2016). A synthesis of qualitative 
studies identified several distinctive stances (Pound et al., 2005). People classified as ‘active 
accepters’ evaluated medicine use, and actively accepted doctor’s recommendations; ‘active 
modifiers’ evaluated and adapted prescribed regimes; ‘passive accepters’ accepted prescribed 
medicine without question; ‘rejecters’ rejected medication altogether.  
In mental health care the meaning of medication is rendered more complex by debates about 
the nature of mental health problems, the presence of coercion and occasional impaired or 
fluctuating capacity (Norvoll & Pedersen, 2016, Szasz, 1970). Evaluating the impact of 
antipsychotic treatment is complex therefore, and users, clinicians and family members may 
have different priorities (Angermeyer et al., 2001, Finn et al., 1990, Rettenbacher et al., 
2004).  
These considerations may explain why shared-decision making in mental health care lags 
behind other areas (Morant et al., 2015). Although  recommended for people with serious 
mental disorders (National Institute for Health and Care Excellence, 2014, The Schizophrenia 
Commission, 2012), mental health service users commonly report feeling they lack choice 
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and are uninvolved in treatment decisions (Goss et al., 2008, Hogman & Sandamas, 2000, 
Olofinjana & Taylor, 2005, Rogers et al., 1998, Usher, 2001). The current study aimed to 
explore experiences of taking antipsychotic medication and how decisions about medication 
are made.  
 
Methods 
Sample  
Participants were recruited from community mental health services in north east London. 
Inclusion criteria were having a psychotic condition, and taking, or having taken 
antipsychotic medication in the last three months. Participants were initially approached by a 
member of the clinical teams, who were provided with the inclusion criteria. Patients were 
purposively sampled according to whether they took medication orally or by depot injection, 
duration of treatment and illness, positive or negative views of medication, and gender. 
Characteristics were reviewed monthly during recruitment to ensure a range of medication 
experiences were captured. Ethical approval was obtained from West London REC 1 
(Reference: 11/LO/0225).  
 
Data collection   
A semi-structured interview schedule was developed in collaboration with an established 
mental health service users group (South Essex Service User Research Group; SE-SURG) 
over the course of three meetings. The focus and wording of questions were informed by 
existing literature and issues that group members considered relevant, expressed in their own 
terms. The final schedule covered: Current medication and medication history; reasons for 
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taking medication; experienced effects of medication (positive and negative); views on long-
term use; deviations from prescribed regimes; and discussions with health practitioners about 
medication, including how decisions are made. 
In order to enhance rapport and openness, interviews were conducted by five service user 
researchers from SE-SURG, with one interview conducted by the study researcher. Most 
interviewers had prior experience of qualitative interviewing and all received additional 
training. Interviewers disclosed their status as mental health service users at the beginning of 
the interview. Participants were reminded about confidentiality, especially at sensitive points 
(such as when discussing self-medication strategies and relations with service providers). 
Data was collected in a single interview, conducted in participants’ homes or out-patient 
clinics and typically lasted for 45 minutes. Interviews were audio-recorded and transcribed.  
 
Data analysis  
Data were analysed using thematic analysis within NVivo software (Braun & Clark, 2006). 
The analytic strategy combined inductive and deductive approaches throughout, allowing 
exploration of initial research questions (such as the effects of taking medication), as well as  
issues that characterised participants’ own experiences. Thus some themes (e.g. fear of 
relapse) were not asked about explicitly, and emerged at several points in the interview. A 
collaborative approach to theme development was adopted, involving independent readings 
of sample transcripts and comparisons of interpretations by NM, KA and JM. We were 
critically aware of our existing preconceptions as academics, researchers and clinicians, and 
integrated service users’ perspectives into early stages of the analytic process: Service user 
interviewers were invited to review, discuss and modify an initial set of emerging themes in a 
half-day meeting, with prior preparation. Issues they identified here, and in their interviewing 
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experiences were integrated into analysis and explored further. These collective processes 
enhanced validity by encouraging high levels of reflexivity (Barry et al., 1999), and ensuring 
that the perspectives of service users informed the analysis (Gillard et al., 2012). 
 
Results 
1. Sample characteristics and medication histories 
Twenty people (13 male, 7 female) were interviewed. Demographic and medication use 
characteristics are shown in Table 1. All participants had a diagnosis of schizophrenia or 
schizoaffective disorder according to medical records. There was a wide range of self-
reported duration of antipsychotic use, with half the sample reporting more than 10 years of 
antipsychotic use. Two participants were subject to Community Treatment Orders (CTOs) 
(participants 07 and 09), a legal measure applying within England and Wales requiring 
acceptance of treatment conditions, commonly including antipsychotic medication. Twelve 
participants received some or all of their medication via long-acting depot injection.  
 
2. Effects of antipsychotic medication 
All but one participant reported at least one positive effect of being on antipsychotic 
medication. Medication was valued for reducing psychotic symptoms, and facilitating a 
“normal” life that included work, independent living or socializing with family or friends.  
“It keeps the symptoms of schizophrenia to a minimum.  And gives me a relatively 
normal life.” (Int18) 
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“With Abilify [aripirazole] it’s really helped. My mom noticed it first, she said it’s like 
oh we’ve got the old [name] back, before I got ill, you know, which was a lovely thing, 
and it was true because I was more acting normal, you know. … I talk to them [family 
and friends] more, umm, looking after myself better, eating properly, sleeping and 
generally getting on with my life.” (Int16)  
A second commonly cited positive effect of medication was relapse prevention. The desire to 
not to be acutely unwell again was often strong, and appeared to be motivated partly by fear 
associated with previous negative experiences of coercion and hospitalization. 
“[I take medication] in order to prevent, I’ve had three sections1 in England, one in 
Australia, previously I’ve always refused to take the antipsychotic medications, partly 
because I didn’t think I needed them and because of the major side effects that I 
receive. This time the message has finally got through to me, take them and hopefully 
I won’t get sectioned again…because I don’t want to go to the hospital again.” 
(Int15) 
Simultaneously, negative experiences of medication were reported by all but two 
respondents. Several described a global state characterized by tiredness, lethargy, 
demotivation and personality change, along with various physical complaints. These effects 
impacted negatively on respondents’ lives, preventing them from doing things they wanted to 
do, such as daily tasks, exercise or socialising.  
“I’ve developed social phobia, I’ve developed diabetes, I’ve got blood pressure, I 
ain’t got many friends … it [medication] just ruins your life… it makes me lazy. It 
makes me groggy, first week it’s just like your body’s hurting, you’ve got no 
                                                          
1 Compulsory admissions to hospital under a section of the Mental Health Act of England and Wales.  
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motivation, makes you lazy…It’s just the pain in the body. If you go to the gym the 
next day it’s double the pain, your legs are hurting from the medicine…The medicine 
hammers you more than the spirits in my life” (Int12) 
For one participant the slowing effect of the medication may have been mirrored in long 
pauses in his account:  
 “[The medication] makes me put on weight actually, (7) 2 reduces my motivation 
(10), changes other people’s attitudes towards me for the worse (4), makes me feel 
depressed (10), sometimes I’m restless sometimes, (4), has a negative effect on my day 
to day living….Uh, umm, (4) it’s very, it sort of relaxes me. It slows me, slows me 
down, it does, it just, it seems to do something mentally that’s, that’s quite sort of (5). 
Think it slows down the thought processes and stuff, I’m not sure what it does. Well 
just that it makes me so physically disabled, so it reduces my ability to function 
normally.” (Int04) 
 
3. Levels of acceptance of antipsychotic medication: The least worst option? 
It was evident from accounts that weighing up the positive and negative effects of medication 
was a central and complex feature of respondents’ lives. For over two thirds of our sample, 
this resulted in a general acceptance of taking antipsychotics, in which medication was 
viewed as ‘the least worst’ option. For half these people, whom we term ‘willing accepters,’ 
the positives effects of medication broadly outweighed negative effects. Only one person in 
this group took medication by depot injection.  
                                                          
2 Lengths of pause in seconds.   
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“The side effects aren't sort of unbearable, I'm able to live with them so it doesn't 
have too bad … they seem to have been keeping me well for about 12 years. So I think 
they do keep the symptoms of schizophrenia low.  So generally speaking, I am glad to 
be taking it, it seems to be working.” (Int18) 
The other half of this ‘accepters’ group, who could be described as ‘resigned accepters’ 
showed more resignation. Many of these people described considerable negative effects that 
impacted more significantly on life quality. Some in this group described having travelled a 
difficult ‘journey of acceptance’ to arrive at their current position.  
“It’s a balancing act and I have to keep reminding myself with those list of negatives, 
you don’t want to go back to hospital and you don’t want to be unwell for 12 months, 
so, so it is a balancing act. Some days I do feel as if the negatives are too much. 
Umm, but I’ve been taking it religiously every day.” (Int15) 
The other third of respondents could be viewed as ‘non-accepters.’ They felt they had little 
choice over taking medication and many did not accept professional views that they were ill 
or needed medication. They rated negative effects as outweighing positive effects, and often 
described feeling ‘forced’ to take medication (see next section). All of these people took 
some or all of their antipsychotic medication by depot injection, and the two people subject to 
CTOs were in this group.  
A common theme across the whole sample, even among those who were generally positive 
about medication currently, was almost universal concern, regarding taking medication on a 
long-term basis. Concerns centered around the long-term effects of antipsychotics on physical 
health, with most people saying they would like to reduce or come off their medication 
eventually.    
11 
 
 “I’m worried about the fact that I might develop diabetes because I’m putting on so 
much weigh all the time, its constant, umm,… I’m worried about those things…. It’s 
going to have a long term detrimental impact.” (Int07)  
4. Limitations to choice and control 
A sense of limited choice and control over taking antipsychotic medication was common 
across interviews, related by respondents to the nature of psychotic illnesses, pressures from 
other people, or taking medication by depot injection. For many respondents, limited choice 
arose from the persistent or recurrent nature of their mental health problems. Most of these 
people were in our category of ‘resigned accepters’, and had adopted an internalized or self-
imposed sense of reduced choice, often related to fears of relapse or returning symptoms.   
“I’d feel scared about stopping the medication because I’m scared of the 
hallucinations and the voices coming back, because they were quite scary for me. So I 
feel like I have to [take medication], but I don’t feel like anyone particular is 
pressurizing me into doing it” (Int14) 
Half of respondents described influence or pressure from other people (mental health 
practitioners and / or family members) as either the main reason or one of several reasons for 
taking medication. This included all the people in the ‘non-accepters’ group (many of whom 
cited external pressure as the only reason they took medication), some ‘resigned accepters’, 
and people who took medication both orally and by depot injection. Several of these people 
said they didn’t want to take medication either because they felt they didn’t need it, or 
because of negative side effects. Perhaps not surprisingly, the two respondents subject to 
CTOs describe this in terms of being ‘forced’ or ‘controlled’ by service providers. For some 
respondents, coercive past experiences shaped their sense of constrained choice:  
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“I don’t think I need medication. I have no option at the moment…I wasn’t taking my 
medication at one time, I refused to take it. I was put in hospital…if I didn’t go in 
voluntary, I would have been sectioned….I don’t think I’m ill….I don’t think I need 
it.” (Int06) 
Others described less coercive forms of pressure from family members or health 
practitioners:  
[I take medication] “because people want me to...Yea, otherwise you get pressured by 
people and I don’t want to upset my family or anything like that.” (Int12) 
Receiving long-acting depot injections was associated with a greater sense of being forced or 
pressured to take medication, and some participants contrasted this with greater possibilities 
for exercising choice and control offered by taking medication orally:  
“I’ve had this illness all my life, I can’t control it at all but I can control how much 
medication [the tablets] I have, that’s one bit of control I’ve got.” (Int17; on depot 
and tablets)  
Underlining this sense of limited choice and control, accounts of self-modification of 
medication regimes were rare, despite respondents being interviewed by a service user who 
provided reassurance about confidentiality and acknowledgement that these practices are 
common. Five participants admitted to relatively minor modifications of medication regimes, 
such as increasing the dose to manage agitation, lowering the dose and missing occasional 
doses due to social plans or the need to be active: 
“I did make a conscious effort a couple of times not to take it because I knew I had 
quite a lot going on the next day, and I needed the energy…I knew I was going out 
during the day and I didn’t want to be tired.” (Int15)  
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5. Discussing medication with professionals: Passive involvement and lack of trust 
Despite concerns about current adverse effects and long-term use of medication, and 
preferences for more choice, a sense of passivity characterised many accounts of discussions 
with prescribers. Several respondents  explicitly said they had never raised concerns about 
long-term use and adverse effects, and their long-term preferences did not feature in 
discussions with prescribers. There was a strong awareness of power inequalities, with many 
participants feeling their concerns were not properly acknowledged or given time for 
discussion, and they were not able to shape decisions about their treatment.  
For some this was a source of frustration and powerlessness. Others conveyed a more passive 
stance that it ‘wasn’t their place’ to raise concerns or appear to challenge the doctor’s agenda. 
Participants described two related issues they felt powerless to address. Firstly, many 
expressed a desire to lower or stop their antipsychotic medication, but felt their psychiatrist 
would not agree to this.   
“I’d like to come off it to be truthful. Come off the whole lot. See how I feel not on it, 
but I don’t think they will ever let me. … When I see my psychiatrist he’s only ever 
asked me how I’m feeling. We never actually discuss the medication or if we do, I 
have to make a point of it because of side effects and things like that, but apart from 
that it’s not really discussed.” [40 seconds more talk] “Sometimes I don’t think that 
they listen, it’s just carry on taking medication, see you in 6 months’ time and carry 
on what you are doing.” (Int17) 
 “Yea, we always discuss it, yea. See I leave it up to her, you see. I never say to her 
about lowering it, I always leave it up to her and that’s about all. We, she asks me 
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questions, about how I been coming on…no I never say about coming off them to 
her…Because I know they won’t do it. They won’t do it, see.” (Int02) 
Secondly, participants reported difficulties in communicating their concerns about adverse 
effects of antipsychotics, including poor life quality associated with these. They felt that 
professionals did not pay enough attention to the physical effects of antipsychotics and often 
prioritized reducing psychotic symptoms over minimizing negative effects.  
“You have to adjust your mind, as I said, like it’s getting to me. It got to me like I was 
really angry not like aggressive or nothing, but just annoyed that no one listens. And 
it just got to stage that you’re going to have to retrain your brain. They are not going 
to listen to you and you just gotta take this injection and make the most of what life 
you’ve got. It’s not much of a life but you’ve got to make the most of it.” (Int12) 
Questions of trust surfaced in several interviews. Those with a history of coercive 
relationships with services, or who were taking medication by depot injection often reported a 
sense of mutual lack of trust between them and service providers. Some participants talked 
about the difficulties of forming relationships with psychiatrists who were constantly 
changing, and the need to build trust with professionals before they could express their 
concerns fully: 
“It’s a different psychiatrist all the time …They don’t know you (inaudible) so you 
can’t have a heart to heart kind of talk, you know what I mean…. I would prefer it if it 
was someone that I would see on a regular basis….Trust, yea, friendship, it’s not 
friendship as such but rapport, you know. You can’t build a rapport once, or once 
now and then, you know. You need to see someone bang on regularly for them, well 
personally for me, to open up to, air me dirty laundry in front of them.” (Int16) 
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There were some accounts of positive interactions and relationships with practitioners 
regarding medication management, expressed by a minority of the willing and resigned 
accepters groups. These people felt the psychiatrist took their concerns about adverse effects 
and physical health more seriously, and that this was reflected in how decisions were made.  
In response to a specific interview question about who initiated discussions about changes to 
medication during psychiatric consultations, a few participants said they felt able to initiate 
these, either directly or via a social worker. However, reflecting the passivity and sense of 
powerlessness described above, others waited for professionals to suggest changes to the dose 
or type of medication, even though they said in interviews that they were not happy and 
would like a change.  
 
Discussion  
Participants in our study reported long and complex histories of medication and service use, 
with profiles that are broadly typical of long-term users of community mental health services 
in the U.K (Mahadun & Marshall, 2008). This patient group constitutes a large proportion of 
mental health service users, whose views and experiences are disproportionately under-
researched.  
Participants valued antipsychotics for reducing symptoms and risk of relapse, but difficult or 
unpleasant effects were near universal, including a debilitating state of lethargy and 
demotivation, and other physical and cognitive effects. These findings are consistent with 
other research involving antipsychotic users (Barbui et al., 2005, Bjornestad et al., 2017, 
Bulow et al., 2016, Carrick et al., 2004, Gray & Deane, 2016, Moncrieff et al., 2009, Rogers 
et al., 1998).  
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Overall, weighing up the positive and negative effects of medication, and the potential 
consequences of not taking it, most of our sample considered medication to be “the least 
worst option” and took medication with various levels of “willing” or “resigned” acceptance. 
However, even those we classified as “willing accepters” described the burden of living with 
adverse effects, and expressed a desire to be medication free in the future. A minority were 
“non-accepters”, some of whom felt formally or informally forced to take medication, and 
were in oppositional relationships with services.  
Although only two people were subject to legal restrictions (CTOs), feelings of 
powerlessness and lack of choice were common, and many described pressure to take 
medication from other people. For many, this sense of obligation had also been internalised in 
the form of (willing, reluctant or resigned) acceptance of medication taking. These factors 
may explain why only a few participants admitted to modifying their medication intake, in 
contrast to other research suggesting high levels of non-adherence (Bulow et al., 2016, 
Cooper et al., 2007), but the finding reflects another recent study with a similar population 
(Priebe et al., 2013). Even in the absence of legal restrictions, it seems an awareness of the 
potential for coercion colours many people’s relationships with mental health treatment and 
services, a situation that has changed little over the last 15-20 years (Rogers et al., 1998, 
Usher, 2001).  
A similar flavour or powerlessness characterised participants’ accounts of reviewing 
medication with professionals. Although some described positive experiences, many felt 
there was little opportunity for their concerns (about side effects or long-term use of 
antipsychotics) to be acknowledged or discussed. Their accounts suggest psychiatrists often 
limit the agenda to current symptom management, with less attention paid to side effects and 
the impact of these on well-being and functioning. Many of our respondents did not feel it 
was possible or their place to disrupt the expected script of the consultation and some 
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reported difficulties in establishing trusting relationships with a series of different 
psychiatrists.  
A greater role in agenda-setting would accord service users more equality in decision-
making. Positive impacts of an intervention to encourage this have been reported (Priebe et 
al., 2007). Strategies for enhancing shared decision-making in relation to antipsychotic 
medication may need to include practitioner training, patient empowerment and attention to 
the requirements of a genuinely therapeutic relationship in order to overcome powerful 
interactional inequalities, and the impacts, for some, of histories of difficult, mistrustful or 
coercive relationships with services (Morant et al., 2015). Enabling broader discussions that 
explore service users’ experiences of antipsychotics, and their long-term preferences and 
goals, key components of genuine shared decision-making; (Charles et al., 1997), are 
consistent with broader cultural shifts towards mental health services that aim to promote 
recovery, patient-centred care and self-management.  
Limitations of the current research include that the sample consisted principally of long-term 
service users. Results are therefore not necessarily generalizable to people with less 
protracted forms of mental ill-health. The purposive sampling technique means the 
distribution of categories of acceptance should not be taken as representative of all 
antipsychotic users. The sampling strategy was designed to allow us to hear the voices of 
those whose experiences may be hard to access, such as those with negative attitudes to 
services and medication. Interviewers’ post-interview reflections and the depth of data 
suggested they were successful in establishing openness and rapport, but respondents may 
still have failed to report instances of non-compliance and adjustments to medication 
regimes. 
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In conclusion, the current study provided an in depth exploration of service users’ views of 
their involvement in decision-making about antipsychotic medication. As well as revealing 
the impacts of taking antipsychotics, it highlights how experiences of medication decision-
making are characterised for many by passivity, perceived limitations of choice, low levels of 
involvement, and a sense of powerlessness.  These factors must be addressed if we are to 
successfully move away from paternalistic and coercive forms of mental health care in the 
future.  
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Table 1: Demographic and medication use characteristics of interview respondents.  
  N (%) 
Age  Mean = 40.3 years; s.d = 11.07 (range 
22-62) 
 
Gender  Male 
Female 
13 (65%)  
7 (35%) 
Ethnicity White British 
Asian 
Afro Caribbean 
15 (75%) 
4 (20%) 
1 (5%) 
Referral service  Generic mental health service 
Early Intervention in Psychosis 
Service  
17 (85%) 
3   (15%) 
Number of 
antipsychotics 
prescribed 
One 
Two  
 
14 (70%) 
6 (30%) 
Method of 
antipsychotic 
delivery 
Depot intramuscular injection 
Oral tablets 
‘Depot’ & oral preparations  
7 (35%) 
8 (40%)  
5 (25%) 
Current 
antipsychotic 
medication 
First generation antipsychotics 
Second generation antipsychotics  
First and second generation 
antipsychotics  
12 (60%) 
5 (25%)  
3 (15%) 
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Duration taking 
antipsychotic 
medication 
0-12 months  
1-5 years 
5-10 years  
>10 years  
4 (20%) 
2 (10%) 
4 (20%) 
10 (50%) 
Other medication 
for mental health 
problems  
Including antidepressants, 
anticonvulsants and sleeping tablets 
6 (30%) 
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